Ownership history in UBS Group AG · 39 quarters on record
This page tracks every 13F SEC filing in which UBS Group AG reported a position in ADAPTIMMUNE THERAPEUTICS PLC (ADAP). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | ADDED | 6,667,358 | +6,604,400 | +10490.2% | 0.00% | $867K | — |
| 2025 Q2 | REDUCED | 62,958 | -949,782 | -93.8% | 0.00% | $15K | — |
| 2025 Q1 | ADDED | 1,012,740 | +870,996 | +614.5% | 0.00% | $200K | — |
| 2024 Q4 | ADDED | 141,744 | +139,927 | +7701.0% | 0.00% | $76K | — |
| 2024 Q3 | UNCHANGED | 1,817 | — | 0% | 0.00% | $2K | — |
| 2024 Q2 | REDUCED | 1,817 | -194,879 | -99.1% | 0.00% | $2K | — |
| 2024 Q1 | ADDED | 196,696 | +172,003 | +696.6% | 0.00% | $311K | — |
| 2023 Q4 | REDUCED | 24,693 | -3,641 | -12.9% | 0.00% | $20K | — |
| 2023 Q3 | REDUCED | 28,334 | -2,646 | -8.5% | 0.00% | $22K | — |
| 2023 Q2 | ADDED | 30,980 | +4,230 | +15.8% | 0.00% | $29K | — |
As of 2025 Q4 — sorted by position size